Last reviewed · How we verify
TS-091
At a glance
| Generic name | TS-091 |
|---|---|
| Sponsor | Taisho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy (PHASE2)
- Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS-091 CI brief — competitive landscape report
- TS-091 updates RSS · CI watch RSS
- Taisho Pharmaceutical Co., Ltd. portfolio CI